scPharmaceuticals Inc. (SCPH)

scPharmaceuticals Inc. was a pharmaceutical company founded in 2013 and based in Burlington, Massachusetts. It concentrated on developing and commercializing products that allow treatments usually given intravenously in a hospital to be delivered subcutaneously outside of it. The name referred to this subcutaneous delivery approach.

Its lead product was FUROSCIX, a formulation of furosemide delivered through an on-body infusor, intended to treat congestion due to fluid overload in adults with chronic heart failure or chronic kidney disease. The infusor is worn on the abdomen and delivers the diuretic over several hours, which can allow patients to be treated at home or in a clinic instead of being admitted to a hospital. The U.S. Food and Drug Administration approved FUROSCIX in October 2022, and the company launched it commercially in 2023.

scPharmaceuticals worked with West Pharmaceutical Services on the SmartDose device platform that underpins the FUROSCIX delivery system. The company also pursued additional subcutaneous antibiotic programs, including scCeftriaxone and a carbapenem-based program, aimed at infections caused by gram-positive and gram-negative organisms. These programs were earlier in development than the marketed heart failure product.

The company completed its initial public offering in November 2017 and listed its common stock on the Nasdaq Global Market under the symbol SCPH. Over the following years it funded clinical work and the commercial launch through equity offerings and debt financing. Sales of FUROSCIX grew after launch, and the product's indication was expanded to cover chronic kidney disease in addition to heart failure.

On August 25, 2025, MannKind Corporation announced a definitive agreement to acquire scPharmaceuticals for $7.20 per share in cash, a transaction valued at roughly $360 million. MannKind, an inhaled-insulin company focused on cardiometabolic and orphan lung disease, said the deal would add an established cardiometabolic product and a commercial presence in cardiology. The structure was a tender offer followed by a merger.

The tender offer was completed, and MannKind announced completion of the acquisition on October 7, 2025, with scPharmaceuticals becoming a wholly owned subsidiary. The shares were removed from trading on Nasdaq, and Nasdaq filed a Form 25 delisting notice with the Securities and Exchange Commission that day. Stockholders who tendered or whose shares were converted in the merger received $7.20 per share in cash.